Title :

Relay oral therapy in febrile urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children: A French multicenter study

Author(s) :

Lignieres, G. [Auteur]
Birgy, A. [Auteur]
Jung, C. [Auteur]
Bonacorsi, S. [Auteur]
Levy, C. [Auteur]
Angoulvant, F. [Auteur]
Grimprel, E. [Auteur]
Dommergues, M. A. [Auteur]
Gillet, Y. [Auteur]
Craiu, I. [Auteur]
Rybak, A. [Auteur]
De Pontual, L. [Auteur]
Dubos, Francois [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Cixous, E. [Auteur]
Gajdos, V. [Auteur]
Pinquier, D. [Auteur]
Andriantahina, I. [Auteur]
Soussan-Banini, V. [Auteur]
Georget, E. [Auteur]
Launay, E. [Auteur]
Vignaud, O. [Auteur]
Cohen, R. [Auteur]
Madhi, F. [Auteur]

Journal title :

PLoS ONE

Abbreviated title :

PLoS One

Volume number :

16

Pages :

e0257217

Publication date :

2021-09-16

ISSN :

1932-6203

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Objectives We need studies assessing therapeutic options for oral relay in febrile urinary tract infection (FUTI) due to ESBL–producing Enterobacteriaceae (ESBL-E) in children. Amoxicillin-clavulanate/cefixime (AC-cefixime) ...
Show more >Objectives We need studies assessing therapeutic options for oral relay in febrile urinary tract infection (FUTI) due to ESBL–producing Enterobacteriaceae (ESBL-E) in children. Amoxicillin-clavulanate/cefixime (AC-cefixime) combination seems to be a suitable option. We sought to describe the risk of recurrence at 1 month after the end of treatment for FUTI due to ESBL-E according to the oral relay therapy used. Materials and methods We retrospectively identified children <18 years who were included in a previous prospective observational multicentric study on managing FUTI due to ESBL-E between 2014 and 2017 in France. We collected whether children who received cotrimoxazole, ciprofloxacin or the AC-cefixime combination as the oral relay therapy reported a recurrence within the first month after the end of treatment. Then, we analyzed the susceptibility drug-testing of the strains involved. Results We included 199 children who received an oral relay therapy with cotrimoxazole (n = 72, 36.2%), ciprofloxacin (n = 38, 19.1%) or the AC-cefixime combination (n = 89, 44.7%). Nine (4.5%) patients had a recurrence within the first month after the end of treatment, with no difference between the 3 groups of oral relay (p = 0.8): 4 (5.6%) cotrimoxazole, 2 (5.3%) ciprofloxacin and 3 (3.4%) AC-cefixime combination. Phenotype characterization of 249 strains responsible for FUTI due to ESBL-E showed that 97.6% were susceptible to the AC-cefixime combination. Conclusions The AC-cefixime combination represents an interesting therapeutic option for oral relay treatment of FUTI due to ESBL-E as the recurrence rate at 1 month after the end of treatment was the same when compared to cotrimoxazole and ciprofloxacin.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2023-11-15T05:52:19Z
2024-01-31T09:24:56Z